Maite L. Docampo-Palacios, Ph.D
I have served as the Lab Director of Colorado Chromatography Labs since February 2023. My role includes leading the R&D team through the entire cycle of cannabinoids and drug development. Also, I support the production department with the design and optimization of the total synthesis of rare cannabinoids, feasibility assessment, risk analysis, and process validation for large-scale production at low cost. I am working on designing and optimizing novel hydrogenated cannabinoids to evaluate the antineoplastic effects on pancreatic ductal adenocarcinoma and lung cancer starting with our leading compounds CCL4 and CCL6.
In Precision Plant Molecules as Director at R&D, I developed high throughput technologies applying the regioselective catalysis as a cost-effective alternative for the commercial manufacture of rare cannabinoids under mild conditions. I was able to successfully bring more than 20 synthetic cannabinoids to the market. Inventing a new catalytic process to synthesize cannabinoids, resulting in a robust intellectual property portfolio.
In my previous works, I designed efficient multistep synthetic procedures of complex organic molecules. These methods facilitate the synthesis of novel heterocycles which have importance as structural motifs in a wide range of molecules with important applications. In this sense, some antiviral, anticancer, and anti-Alzheimer compounds were synthesized as pre-clinical candidates.
Maite L. Docampo-Palacios, Ph.D
I have served as the Lab Director of Colorado Chromatography Labs since February 2023. My role includes leading the R&D team through the entire cycle of cannabinoids and drug development. Also, I support the production department with the design and optimization of the total synthesis of rare cannabinoids, feasibility assessment, risk analysis, and process validation for large-scale production at low cost. I am working on designing and optimizing novel hydrogenated cannabinoids to evaluate the antineoplastic effects on pancreatic ductal adenocarcinoma and lung cancer starting with our leading compounds CCL4 and CCL6.
In Precision Plant Molecules as Director at R&D, I developed high throughput technologies applying the regioselective catalysis as a cost-effective alternative for the commercial manufacture of rare cannabinoids under mild conditions. I was able to successfully bring more than 20 synthetic cannabinoids to the market. Inventing a new catalytic process to synthesize cannabinoids, resulting in a robust intellectual property portfolio.
In my previous works, I designed efficient multistep synthetic procedures of complex organic molecules. These methods facilitate the synthesis of novel heterocycles which have importance as structural motifs in a wide range of molecules with important applications. In this sense, some antiviral, anticancer, and anti-Alzheimer compounds were synthesized as pre-clinical candidates.